Targeting a novel Plasmodium falciparum purine recycling pathway with specific immucillins.

TitleTargeting a novel Plasmodium falciparum purine recycling pathway with specific immucillins.
Publication TypeJournal Article
Year of Publication2005
AuthorsTing L-M, Shi W, Lewandowicz A, Singh V, Mwakingwe A, Birck MR, Ringia EATaylor, Bench G, Madrid DC, Tyler PC, Evans GB, Furneaux RH, Schramm VL, Kim K
JournalJ Biol Chem
Volume280
Issue10
Pagination9547-54
Date Published2005 Mar 11
ISSN0021-9258
KeywordsAdenine, Adenosine Deaminase, Amino Acid Sequence, Animals, Conserved Sequence, Escherichia coli, Humans, Hypoxanthine, Inosine, Methylthioinosine, Molecular Sequence Data, Plasmodium falciparum, Purine-Nucleoside Phosphorylase, Purines, Sequence Alignment, Sequence Homology, Amino Acid
Abstract

Plasmodium falciparum is unable to synthesize purine bases and relies upon purine salvage and purine recycling to meet its purine needs. We report that purines formed as products of polyamine synthesis are recycled in a novel pathway in which 5'-methylthioinosine is generated by adenosine deaminase. The action of P. falciparum purine nucleoside phosphorylase is a convergent step of purine salvage, converting both 5'-methylthioinosine and inosine to hypoxanthine. We used accelerator mass spectrometry to verify that 5'-methylthioinosine is an active nucleic acid precursor in P. falciparum. Prior studies have shown that inhibitors of purine salvage enzymes kill malaria, but potent malaria-specific inhibitors of these enzymes have not been described previously. 5'-Methylthio-immucillin-H, a transition state analogue inhibitor that is selective for malarial relative to human purine nucleoside phosphorylase, kills P. falciparum in culture. Immucillins are currently in clinical trials for other indications and may also have application as anti-malarials.

DOI10.1074/jbc.M412693200
Alternate JournalJ Biol Chem
PubMed ID15576366